TSNL.F Stock Overview

Develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. More details

TSNL.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	4/6
Financial Health	6/6
Dividends	3/6

Rewards

Earnings are forecast to grow 22.31% per year

Earnings grew by 73.7% over the past year

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

Dividend of 2.23% is not well covered by earnings

My Notes

Capture your thoughts, links and company narrative

Tristel plc Competitors

OraSure Technologies

NasdaqGS:OSUR

US$275.3m

Utah Medical Products

NasdaqGS:UTMD

US$208.3m

Avanos Medical

NYSE:AVNS

US$691.4m

Embecta

NasdaqGS:EMBC

US$1.2b

Price History & Performance

Summary of share price highs, lows and changes for Tristel
Historical stock prices
Current Share Price	UK£5.29
52 Week High	UK£5.29
52 Week Low	UK£5.09
Beta	0.26
1 Month Change	0%
3 Month Change	n/a
1 Year Change	4.13%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-11.69%

Recent updates

Shareholder Returns

	TSNL.F	US Medical Equipment	US Market
7D	0%	2.7%	2.8%
1Y	4.1%	10.6%	24.6%

Return vs Industry: TSNL.F underperformed the US Medical Equipment industry which returned 10.5% over the past year.

Return vs Market: TSNL.F underperformed the US Market which returned 25.3% over the past year.

Price Volatility

Is TSNL.F's price volatile compared to industry and market?
TSNL.F volatility
TSNL.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.4%
10% least volatile stocks in US Market	3.1%

Stable Share Price: TSNL.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine TSNL.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	208	Paul Swinney	tristel.com

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand.

Tristel plc Fundamentals Summary

How do Tristel's earnings and revenue compare to its market cap?
TSNL.F fundamental statistics
Market cap	US$289.70m
Earnings (TTM)	US$7.81m
Revenue (TTM)	US$51.12m

37.1x

P/E Ratio

5.7x

P/S Ratio

Is TSNL.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TSNL.F income statement (TTM)
Revenue	UK£39.49m
Cost of Revenue	UK£6.91m
Gross Profit	UK£32.58m
Other Expenses	UK£26.54m
Earnings	UK£6.04m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.13
Gross Margin	82.49%
Net Profit Margin	15.29%
Debt/Equity Ratio	0%

How did TSNL.F perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

103%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/08/18 05:04
End of Day Share Price	2024/05/21 00:00
Earnings	2023/12/31
Annual Earnings	2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tristel plc is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Simon Miller	Blue Oar Securities
Christopher Donnellan	Cavendish
Sebastien Jantet	CGS International